Patents Assigned to Purdue Pharmaceutical Products, L.P.
-
Publication number: 20240082220Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.Type: ApplicationFiled: August 9, 2023Publication date: March 14, 2024Applicant: Purdue Pharmaceutical Products L.P.Inventors: Thomas Mehrling, Rosaria De Filippi, Antonio Pinto
-
Patent number: 11766424Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.Type: GrantFiled: February 24, 2022Date of Patent: September 26, 2023Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Mehrling, Rosaria De Filippi, Antonio Pinto
-
Patent number: 11559516Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: March 25, 2021Date of Patent: January 24, 2023Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 11541038Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: August 14, 2020Date of Patent: January 3, 2023Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 11419853Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof: for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.Type: GrantFiled: March 26, 2015Date of Patent: August 23, 2022Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Mehrling, Claudio Festuccia
-
Patent number: 11266631Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotin and said combination for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said combination.Type: GrantFiled: October 11, 2016Date of Patent: March 8, 2022Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Thomas Mehrling, Rosaria De Filippi, Antonio Pinto
-
Patent number: 10744120Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: May 26, 2015Date of Patent: August 18, 2020Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 10507205Abstract: The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an inseparable combination of an opiate and at least one opiate antagonists with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for prevention of non-oral opiate abuse in opiate addicts.Type: GrantFiled: June 20, 2016Date of Patent: December 17, 2019Assignee: Purdue Pharmaceutical Products L.P.Inventor: Lars Hermann
-
Patent number: 10406138Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: May 21, 2018Date of Patent: September 10, 2019Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 10118901Abstract: The present invention relates to a class of hydroxamic acid compounds of Formula (I), which act as alkylating agents and/or inhibitors of the HDAC pathway, having potential utility in the treatment of a neoplastic disease and immune diseases.Type: GrantFiled: January 31, 2013Date of Patent: November 6, 2018Assignee: Purdue Pharmaceutical Products L.P.Inventors: Yu Chen, Yi Chen
-
Patent number: 9993482Abstract: The present invention is directed to a combination comprising a class III receptor tyrosine kinase inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: May 26, 2015Date of Patent: June 12, 2018Assignee: Purdue Pharmaceutical Products L.P.Inventor: Thomas Jorg Mehrling
-
Publication number: 20170296513Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: May 26, 2015Publication date: October 19, 2017Applicant: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20170151218Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: ApplicationFiled: May 26, 2015Publication date: June 1, 2017Applicant: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Publication number: 20170128741Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.Type: ApplicationFiled: January 13, 2017Publication date: May 11, 2017Applicant: Purdue Pharmaceutical Products L.P.Inventors: Llew KELTNER, Jay WINSHIP, Erik HAGSTROM, Frank ZHENG, James C. CHEN, Joseph M. HOBBS
-
Publication number: 20160213945Abstract: A photoreactive agent and a drug therapy device including a support member configured to pass through a urethra having proximal and distal ends and a longitudinal internal lumen. A light generator carried by the support member, potted within the lumen, and positioned within the urethra to deliver light to the prostate. The light generator generates a light band with a peak at a preselected wavelength. A power source external to the support member powers the light generator. The positioning element locates the support member within the urethra. A transparent/translucent, integral window is positioned proximate to the prostate and allows light to pass through. The window extends 360 degrees radially from the support member. The light generator has at least LEDs or LOs having a dimension of approximately 0.3 mm×0.3 mm×0.1 mm (length×width×thickness).Type: ApplicationFiled: April 5, 2016Publication date: July 28, 2016Applicant: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Phillip Burwell, Zihong Guo, Jennifer K. Matson, Steven Ross Daly, David B. Shine, Gary Lichttenegger, Jean Bishop, Nick Yeo, Hugh Narciso, Llew Keltner, Jay Winship, Erik Hagstrom, Frank Zheng, James C. Chen, Joseph M. Hobbs
-
Patent number: 9376395Abstract: The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.Type: GrantFiled: September 14, 2012Date of Patent: June 28, 2016Assignee: Purdue Pharmaceuticals Products L.P.Inventors: Yu Chen, Lan Yang, Feiyu Feng, Qiufu Ge, Dianwu Guo, Yi Chen
-
Patent number: 9149651Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.Type: GrantFiled: January 8, 2008Date of Patent: October 6, 2015Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Llew Keltner, James C. Chen
-
Patent number: 9096627Abstract: The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.Type: GrantFiled: November 8, 2013Date of Patent: August 4, 2015Assignee: Purdue Pharmaceutical Products L.P.Inventors: Yu Chen, Yi Chen
-
Patent number: RE46144Abstract: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.Type: GrantFiled: December 17, 2015Date of Patent: September 13, 2016Assignee: Purdue Pharmaceutical Products L.P.Inventors: Yu Chen, Yi Chen
-
Patent number: RE46504Abstract: A light delivery system to provide light treatment to a patient includes a catheter assembly having a plurality of light sources that transmit light towards a target site within a patient. In one embodiment, the light delivery system has a plurality of light sources mounted to a flexible transparent base that extends at least partially through a distal tip of the catheter assembly. The light sources can be wire bonded or mounted in a flip chip arrangement onto the base. In one embodiment to produce the distal tip, an array of light energy sources can be held by an array of holders of a fixture device. A vacuum is applied to secure each light energy source in a corresponding holder. While the vacuum is applied, the energy sources are electrically connected by wire bonding. The vacuum can be reduced or stopped thereby permitting removal of the light energy sources from the fixture device.Type: GrantFiled: April 1, 2016Date of Patent: August 8, 2017Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.Inventors: Jonathan S. Dahm, William Louis Barnard, James C. Chen, David B. Shine